← back to search

Ann‐Sofie Jemth

Science for Life Laboratory · SE
Area of research
Molecular Biology · Cancer Research
Research interest
Research interests include DNA Repair Mechanisms, Biochemical and Molecular Research, Cancer, Hypoxia, and Metabolism, and RNA modifications and cancer.
h-index
28
citations
4,166
works
111
NIH funding
primary concept
email

Recent publications

Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells
Nature Metabolism 2023cited by 50position: middledoi
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
Nature Cancer 2022cited by 101position: middledoi
Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function
Science 2022cited by 74position: middledoi
The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform‐Selective Inhibitors
ChemMedChem 2022cited by 26position: middledoi
NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir
Cell chemical biology 2021cited by 23position: middledoi
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
Nucleic Acids Research 2020cited by 58position: middledoi
Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses
Viruses 2020cited by 41position: middledoi
Structural basis of inhibition of the human serine hydroxymethyltransferase <scp>SHMT</scp>2 by antifolate drugs
FEBS Letters 2019cited by 49position: middledoi
Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation
Science 2018cited by 229position: middledoi
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
Nature Communications 2018cited by 122position: middledoi
A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family
Nature Communications 2017cited by 170position: middledoi
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nature Medicine 2017cited by 141position: middledoi
Validation and development of MTH1 inhibitors for treatment of cancer
Annals of Oncology 2016cited by 145position: middledoi
Processing of protein ADP-ribosylation by Nudix hydrolases
Biochemical Journal 2015cited by 137position: middledoi
Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2
Nature Communications 2015cited by 114position: middledoi
MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool
Nature 2014cited by 529position: middledoi
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
Nature 2014cited by 390position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Thomas Helleday · Science for Life Laboratory9 papers (2014–2022)Pål Stenmark · Lund University6 papers (2015–2022)Ulrika Warpman Berglund · Orexo (Sweden)4 papers (2014–2021)Megan Carter · University of Kentucky3 papers (2015–2018)Evert Homan · Science for Life Laboratory3 papers (2018–2022)Nicholas C.K. Valerie · Karolinska University Hospital3 papers (2015–2021)Brent D. G. Page · University of British Columbia3 papers (2015–2021)Olga Loseva · Science for Life Laboratory3 papers (2015–2018)Sean G. Rudd · Science for Life Laboratory2 papers (2018–2021)Matthieu Desroses · Sprint Bioscience (Sweden)2 papers (2015–2021)Emma Rose Scaletti · University of Otago2 papers (2019–2022)Olov Wallner · Karolinska University Hospital2 papers (2018–2020)Martin Scobie · Orexo (Sweden)2 papers (2018–2021)Ingrid Almlöf · Karolinska University Hospital2 papers (2018–2021)Kia Strömberg · Fox Chase Cancer Center2 papers (2014–2018)Elisée Wiita · Karolinska University Hospital2 papers (2020–2022)Paweł Baranczewski · Uppsala University1 papers (2018–2018)Bo Lundgren · Science for Life Laboratory1 papers (2017–2017)Marjo-Riitta Puumalainen · Science for Life Laboratory1 papers (2020–2020)José Manuel Calderón‐Montaño · Universidad de Sevilla1 papers (2017–2017)